Spike Protein News and Research

RSS

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers in the United States have demonstrated the long-term durability of the antibody responses elicited by Moderna’s mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 May 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Although several monoclonal antibodies against the SARS-CoV-2 spike protein have been developed and clinically tested, little is known about antibodies to the nucleocapsid protein. In a paper published recently in the journal Nature Communications, researchers report a human monoclonal antibody that targets the nucleocapsid protein.

17 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 May 2021

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Researchers in Germany have demonstrated the preclinical effectiveness of a next-generation coronavirus disease 2019 (COVID-19) vaccine at enhancing antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

The importance of computational modeling in the prediction of the course of the ongoing COVID-19 pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response.

13 May 2021

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

In a paper published on the bioRxiv* preprint server, researchers report new monoclonal antibodies that target the S2 subunit and that have broad neutralization activity against several betacoronaviruses.

13 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Scientists unveil new Ebola virus vaccine design

Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health.

13 May 2021

Inexpensive test for rapid detection of COVID-19 with 90% accuracy

A low-cost, rapid diagnostic test for COVID-19 developed by Penn Medicine provides COVID-19 results within four minutes with 90 percent accuracy.

12 May 2021

Spread of minority SARS-CoV-2 variants in New York City

Viruses mutate to survive. But not all mutations are beneficial to the virus. On the other hand, some mutations such as N501Y and E484K on the spike protein propelled specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants to ‘variant of concern’ status, due to their ability to increase transmission and weaken the response of neutralizing antibodies.

12 May 2021

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

The emergence of this variant highlighted the uneven pace of mutation and selection of variants. New bioinformatics tools are the need of the hour to clarify this and confirm a dynamic evolution by tracking the mutation rates of the spike protein. It generally takes 1 – 6 months for current variants causing COVID-19 case peaks and deaths to survive the pressure of selection.

11 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers have designed a new class of TMPRSS2 inhibitors that have shown broad antiviral activity against coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 May 2021

MIT researchers generate the complete gene annotation of SARS-CoV-2 genome

In early 2020, a few months after the Covid-19 pandemic began, scientists were able to sequence the full genome of the virus that causes the infection, SARS-CoV-2. While many of its genes were already known at that point, the full complement of protein-coding genes was unresolved.

11 May 2021

Spike Protein News and Research

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Nanotechnology and COVID-19 diagnosis and treatment

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Enhanced version of CureVac’s COVID-19 vaccine could help address supply shortages

Antibodies generated by malaria cross-react with SARS-CoV-2

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Scientists unveil new Ebola virus vaccine design

Inexpensive test for rapid detection of COVID-19 with 90% accuracy

Spread of minority SARS-CoV-2 variants in New York City

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

MIT researchers generate the complete gene annotation of SARS-CoV-2 genome

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News